PDF(Pubmed)
Abstract：
Reperfusion stroke therapy is a modern treatment that involves thrombolysis and the mechanical removal of thrombus from the extracranial and/or cerebral arteries, thereby increasing penumbra reperfusion. After reperfusion therapy, 46% of patients are able to live independently 3 months after stroke onset. MicroRNAs (miRNAs) are essential regulators in the development of cerebral ischemia/reperfusion injury and the efficacy of the applied treatment. The first aim of this study was to examine the change in serum miRNA levels via next-generation sequencing (NGS) 10 days after the onset of acute stroke and reperfusion treatment. Next, the predictive values of the bioinformatics analysis of miRNA gene targets for the assessment of brain ischemic response to reperfusion treatment were explored. Human serum samples were collected from patients on days 1 and 10 after stroke onset and reperfusion treatment. The samples were subjected to NGS and then validated using qRT-PCR. Differentially expressed miRNAs (DEmiRNAs) were used for enrichment analysis. Hsa-miR-9-3p and hsa-miR-9-5p expression were downregulated on day 10 compared to reperfusion treatment on day 1 after stroke. The functional analysis of miRNA target genes revealed a strong association between the identified miRNA and stroke-related biological processes related to neuroregeneration signaling pathways. Hsa-miR-9-3p and hsa-miR-9-5p are potential candidates for the further exploration of reperfusion treatment efficacy in stroke patients.
摘要：
再灌注中风治疗是一种现代治疗方法，涉及溶栓和从颅外和/或脑动脉机械去除血栓，从而增加半影再灌注。再灌注治疗后,46%的患者能够在卒中发病后3个月独立生活。MicroRNAs(miRNAs)是脑缺血/再灌注损伤的发展过程中必不可少的调控因子,也是应用治疗的功效调控因子。这项研究的第一个目的是在急性中风和再灌注治疗发作后10天通过下一代测序（NGS）检查血清miRNA水平的变化。接下来,对miRNA基因靶标的生物信息学分析对评估再灌注治疗后脑缺血反应的预测价值进行了探讨。在中风发作和再灌注治疗后第1天和第10天从患者收集人血清样品。对样品进行NGS,然后使用qRT-PCR验证。差异表达的miRNA(DEmiRNA)用于富集分析。与中风后第1天的再灌注治疗相比，Hsa-miR-9-3p和hsa-miR-9-5p表达在第10天下调。miRNA靶基因的功能分析揭示了鉴定的miRNA和与神经再生信号通路相关的卒中相关的生物过程之间的强关联。Hsa-miR-9-3p和hsa-miR-9-5p是进一步探索中风患者再灌注治疗功效的潜在候选者。
